Evidence map›Paper›PMID 30444903›Full record

Observational studyPloS one2018

Serodiscordant partnerships and opportunities for pre-exposure prophylaxis among partners of women and men living with HIV in St. Petersburg, Russia.

Natalia Gnatienko, Jennifer A Wagman, Debbie M Cheng, Angela R Bazzi, Anita Raj, Elena Blokhina, Olga Toussova, Leah S Forman, Dmitry Lioznov, Carly Bridden and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Natalia GnatienkoDepartment of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, Boston Medical Center, Boston, MA, United States of America.
Jennifer A WagmanDepartment of Medicine, Division of Global Public Health, University of California San Diego School of Medicine, IOA Building, San Diego, CA, United States of America.
Debbie M ChengDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America.
Angela R BazziDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, United States of America.
Anita RajDepartment of Medicine, Division of Global Public Health, University of California San Diego School of Medicine, IOA Building, San Diego, CA, United States of America.
Elena BlokhinaLaboratory of Clinical Pharmacology of Addictions, First Pavlov State Medical University, St. Petersburg, Russian Federation.
Olga ToussovaLaboratory of Clinical Pharmacology of Addictions, First Pavlov State Medical University, St. Petersburg, Russian Federation.
Leah S FormanBiostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, United States of America.
Dmitry LioznovSmorodintsev Research Institute of Influenza, St. Petersburg, Russian Federation.
Carly BriddenDepartment of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, Boston Medical Center, Boston, MA, United States of America.
Meg SullivanDepartment of Medicine, Section of Infectious Diseases, Boston University School of Medicine/Boston Medical Center, Boston, MA, United States of America.
Kendall BryantHIV/AIDS Research, National Institute on Alcohol Abuse and Alcoholism, National Institute of Health, Bethesda, MD, United States of America.
Jeffrey H SametDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, United States of America.
Judith I TsuiDepartment of Medicine, Section of General Internal Medicine, University of Washington School of Medicine and Harborview Hospital, Seattle, WA, United States of America.
Boston University · USFirst Pavlov State Medical University of St. Petersburg · RUBoston Medical Center · USUniversity of California, San Diego · USHarborview Medical Center · USNational Institute on Alcohol Abuse and Alcoholism · US

Funding

URBAN ARCH 4/5 Russia Cohort-Targeting HIV-comorbidities with Pharmacotherapy to Reduce Alcohol and Tobacco Use in HIV-infected RussiansU01AA020780 · NIAAA · BOSTON MEDICAL CENTER · PI FREIBERG, MATTHEW S, SAMET, JEFFREY H. · 2011 to 2021
$4.4M
URBAN ARCH (2/5) Biostatistics and Data Management Core (BDM)U24AA020779 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHENG, DEBBIE M. · 2011 to 2020
$3.6M
URBAN ARCH (1/5) Administrative Coordinating Core (Admin Core)U24AA020778 · NIAAA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2011 to 2020
$3.5M
Zinc for HIV Disease among Alcohol Users -An RCT in the Russia ARCH CohortU01AA021989 · NIAAA · BOSTON MEDICAL CENTER · PI FREIBERG, MATTHEW S, SAMET, JEFFREY H. · 2012 to 2016
$3.3M
Preventing HIV infection among people who inject drugs during COVID-19K01DA043412 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAZZI, ANGELA ROBERTSON · 2017 to 2021
$934k
Alcohol Epidemiology and Pilot Intervention to Reduce Alcohol, IPV and HIV in Women in UgandaK01AA024068 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WAGMAN, JENNIFER ANN · 2015 to 2019
$917k
HCV and Pain in Substance Users With and Without HIVK23DA027367 · NIDA · BOSTON MEDICAL CENTER · PI TSUI, JUDITH · 2010 to 2013
$651k
NIAAA NIH HHS K01 AA024068NIAAA NIH HHS U01 AA020780NIAAA NIH HHS U01 AA021989NIAAA NIH HHS U24 AA020778NIAAA NIH HHS U24 AA020779NIDA NIH HHS K01 DA043412NIDA NIH HHS K23 DA027367
6 · The paper itself

Abstract

objectiveTo describe the frequency of being partnered and having an HIV-negative partner, and whether this differed by gender, among a cohort of persons living with HIV (PLWH) who have ever injected drugs; to describe awareness of HIV pre-exposure prophylaxis (PrEP) and perceived partner interest in PrEP.

settingSecondary analyses of an observational cohort study of PLWH who have ever injected drugs in St. Petersburg, Russia.

methodsPrimary outcomes were 1) being partnered and 2) being in a serodiscordant partnership. The main independent variable was gender. Multivariable GEE logistic regression models were fit for binary outcomes, adjusted for age, income, education, and recent opioid use. Descriptive analyses were performed for partners' HIV status, substance use, sex risk behaviors, and awareness of PrEP for a subset of participants.

resultsAt baseline, 50% (147/296) reported being in a partnership, and of those, 35% were in a serodiscordant partnership. After adjustment, women had significantly higher odds of being partnered compared to men (aOR = 3.12; 95% CI: 1.77, 5.51), but there were no significant gender differences in the odds of being in a serodiscordant partnership (aOR = 0.58; 95% CI: 0.27, 1.24). Among a sub-sample of participants queried (n = 56), 25% were aware of PrEP for prevention of sexual HIV transmission and 14% for prevention of injection-related transmission.

conclusionAlthough half of our sample were partnered and one third of these partnerships were serodiscordant, PrEP awareness was low. Substantial opportunities for HIV prevention exist among PLWH who have ever injected drugs in Russia and their HIV-negative partners. Given the high proportion of HIV-negative partners among this ART-naïve sample, efforts to address the associated inherent risks, such as couples-based interventions, are needed to increase condom use, PrEP awareness, or uptake of other HIV-prevention modalities (e.g., ART for the HIV-positive partner).

Indexed as

Health Risk BehaviorsHIV-1HIV InfectionsHIV SerosortingAdolescentAdultAgedAge FactorsFemaleFollow-Up StudiesHumansMaleMiddle AgedRussiaSex FactorsSocioeconomic Factors

Identifiers

PMID30444903
PMCPMC6239322
OpenAlexW2901202905

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.